We revisit Heron in the paragraphs below and outline how we plan to action this recent news. San Diego-based Heron Therapeutics has a target action date of June 26 for its resubmission of its NDA for HTX-011 for postoperative pain.
Heron Therapeutics (NASDAQ: HRTX) has recently received a number of price target changes and ratings updates: 6/30/2020 – Heron Therapeutics had its price target lowered by analysts at SVB Leerink LLC from $26.00 to $19.00. NASDAQ Updated Jul 7, 2020 9:41 PM ET (5:30 a.m. PT). 18,20 € +2,82% +0,50 € 19.06.20 17:36:19 Frankfurt | Orderbuch | Mehr Kurse » They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Heron Therapeutics, Inc.’s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs.The US$1.8b market-cap company’s loss lessens since it announced a -US$204.7m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$193.3m, as it approaches … Shares of Heron Therapeutics Inc. HRTX, -3.60% fell 31% on Wednesday after the biotech said the FDA would not approve the new drug application for its pain-management drug HTX-011 in its present form.
June 29, 2020 GMT.
View the real-time HRTX price chart on Robinhood and decide if you want to buy or sell commission-free.
Heron Therapeutics had a negative net margin of 138.31% and a negative return on equity of 56.85%. We are currently developing and commercializing pharmaceutical products for patients suffering from cancer or postoperative pain.Our goal is to develop each of our products with patients' needs at the center of our focus, and to deliver products with best-in-class therapeutic potential. Heron Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. Invesco Ltd. increased its holdings in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 8.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The conference call can be accessed by dialing 877-311-5906 for domestic callers and 281-241-6150 for international callers.
HRTX | Complete Heron Therapeutics Inc. stock news by MarketWatch.
ET (5:30 a.m. PT).
Heron Therapeutics’ HTX-011 for Post-Operative Pain. Heron Therapeutics, Inc.’s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs.The US$1.8b market-cap company’s loss lessens since it announced a -US$204.7m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$193.3m, as it approaches breakeven. Product Portfolio. They now have an “outperform” rating on the stock.
Heron Therapeutics, Inc.’s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs.The US$1.8b market-cap company’s loss lessens since it announced a -US$204.7m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$193.3m, as it approaches breakeven. 6/29/2020 – Heron Therapeutics is now covered by analysts at Stifel […]
June 04, 2020 | Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 …
HERON THERAPEUTICS (A1XB6K | US4277461020) mit aktuellem Aktienkurs, Charts, News und Analysen. Heron Therapeutics Inc. HRTX 14.98 0.01 (0.07%). We are currently developing and commercializing pharmaceutical products for patients suffering from cancer or postoperative pain.Our goal is to develop each of our products with patients' needs at the center of our focus, and to deliver products with best-in-class therapeutic potential. View the latest news about Heron Therapeutics.
Product Portfolio. The move came on solid volume too with far more shares changing hands than in a normal session.
Heron Therapeutics, Inc. (NASDAQ:HRTX) went up by 0.27% from its latest closing price when compared to the 1-year high value of $26.81 and move down -78.61%, while HRTX stocks collected +5.30% of gains with the last five trading sessions. Please provide the operator with the passcode 9591606 to join the conference call.
The Investor Relations website contains information about Heron Therapeutics's business … Heron Therapeutics will host a conference call and webcast today, May 1, 2019, at 8:30 a.m. 6,147 people own Heron Therapeutics on Robinhood on July 7, 2020. Company Overview Heron Therapeutics is a " Tier 3 " … This stock, which remained volatile and traded within the range of $14.26 –$21.47 in the past one-month time frame, witnessed a sharp increase yesterday. Recent News.
Get the latest Heron Therapeutics, Inc. (HRTX) stock news and headlines to help you in your trading and investing decisions.